The most common form of hyperthyroidism in the US is Graves Disease. In the recent months, it has seen a promising alternative to surgery and radioactive iodine therapy in the form of the drug, methimazole. Methimazole is an anti-thyroid drug that is usually given to patients prior to undergoing surgical thyroid removal in order to lower thyroid hormone levels in the body.
In the current medical practice, surgical removal of the thyroid gland and radioactive iodine therapy are considered the best options in the long run. However, in some European practices, staying on oral methimazole indefinitely is considered a better treatment option. This is especially true for patients who are not good candidates for surgery and radioactive therapy. Given that patients who undergo surgery and radioactive therapy usually become hypothyroid (decreased thyroid hormone levels), they need to take a supplementary thyroid hormone daily for the rest of their lives.
Now patients are faced with two options: take an antithyroid medication such as methimazole for the rest of their lives or undergo surgery and radiation treatments and then take thyroid supplements indefinitely. Either way they have to take pills everyday which resolves the issue of better convenience and therapy adherence. These two options are tied in this score. Now what about side effects? Methimazole CAS# 60-56-0 has a better side effect profile than the other two. Although it is known to cause rashes and headaches, surgery and radiation do not even stand close scrutiny since the former has inherent risks and the latter strongly increases the risk of the eye disorder, Grave’s opthalmopathy.
A study published in the European Journal of Endocrinology that compared the long term effects of 10 year therapy with methimazole with radioactive iodine therapy found that both treatments produced similar thyroid levels, cost of treatments and blood analysis results. What’s more, the patients treated with radioactive iodine had higher levels of LDL when lipid profiles were obtained as well as decreased bone densities. Except for the rare blood dyscrasias it causes, methimazole is a good alternative to the two options. Doctors and health professionals believe that it will only be a matter of time before this becomes the treatment of choice.
These results bring us down to Methimazole CAS# 60-56-0, a research molecule supplied by LGM Pharma. Apparently, the judge is still out on this drug’s role in the long term treatment of Grave’s disease. However, initial studies such as the one mentioned above as well as the steady supply chain provided by LGM Pharma to the extended research and development of this drug pave the way for its increasing importance in the treatment of Grave’s disease.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.